Exchange: NASDAQ·Updated 07:52 PM EST

TWST News

News
all
press releases
Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech
Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech...
SeekingAlpha
Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech
Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech...
SeekingAlpha
More News
Barclays dropped their target price on shares of Twist Bioscience from $215.00 to $130.00 and set an "overweight" rating for the company in a report on Monday...
MarketBeat
William Blair Investment Management LLC reduced its holdings in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 33.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,454,117 shares of the company's stock...
MarketBeat
Russell Investments Group Ltd. increased its position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 190.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 283,910 shares...
MarketBeat
ARK bought about $8.79 million in Archer, $5.59 million in Rocket Lab and $4.74 million in Kratos, with Archer leading purchases by share count.
Stocktwits
Key PointsFourth-quarter revenue grew 28% year over year to $126.6 million...
Nasdaq News: Markets
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Twist Bioscience (TWST) delivered earnings and revenue surprises of +25.58% and +2.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (Twist or the Company), a mid-cap growth and value healthcare company, today announced that a total of 17,681 restricted stock units (RSUs) will be granted to 19 recently hired individuals, in each case...
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor...
Business Wire

Advertisement|Remove ads.